A Phase 3 interventional study of Placebo and mRNA-1345 in Respiratory Syncytial Virus, sponsored by ModernaTX, Inc.. Completed at 62 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-30.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases — none open to participants now, none under way, none of them phase 3. mRNA-1345 respiratory syncytial virus vaccine · Virus Diseases.
Among the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases, this one is the 2nd largest by enrollment, is one of 3 that started in 2022, is one of 4 in phase 3, and was the 3rd registered.
656 studies on the registry are indexed under Virus Diseases; 83 are open to participants now.
Browse Virus Diseases studies →None of the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases is open now. The open studies under Virus Diseases, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 63 Virus Diseases studies recruiting now, 29 (46%) set no upper age limit and 22 (35%) stop at 75 or younger; 27 take children under 18; 26 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 5
First in 2020; this study’s year is marked. 3 started in 2022.
This study's enrollment of 3,317 is above the median of 100 across 464 interventional studies indexed under Virus Diseases.
Median enrollment 579 across the 10 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
47 studies in Virus Diseases by Moderna, Inc.: 2 open now, 6 under way, 1 of them phase 3. Of 40 finished, 17 (43%) have results posted.
Among the 47 studies in Virus Diseases by Moderna, Inc., this one is the 11th largest by enrollment of the 37 interventional ones that give a count, is one of 9 that started in 2022, is one of 11 in phase 3, and was the 19th registered.
Moderna, Inc.’s Virus Diseases studies by the year they started, since 2019.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases, from their registry updates:
Among Moderna, Inc.’s 47 in Virus Diseases:
This tab as a report to print or save as PDF → With an account.
The main purposes of Part A of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine (Afluria® Quadrivalent); to evaluate the impact of coadministered influenza vaccine on the immune response to RSV-A; and to evaluate the impact of coadministered RSV vaccine on the immune response to influenza.
The main purposes of Part B of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with mRNA-1273.214; to evaluate the effect of coadministered mRNA-1273.214 on the immune response to RSV-A; and to evaluate the effect of coadministered RSV vaccine on the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The main purposes of Part C (single arm, open-label) of this study are to evaluate the safety and tolerability of a booster dose (BD) of mRNA-1345 administered at 1 Year following a primary dose; to evaluate the immune response to RSV-A of a BD of mRNA 1345 administered at 1 Year following a primary dose; and to evaluate the immune response to RSV-B of a BD of mRNA-1345 administered at 1 Year following a primary dose.
Key Inclusion Criteria:
Parts A and B both:
Part B only:
Part C:
Key Exclusion Criteria:
Part A:
Part B:
Parts A and B both:
Part C:
Other inclusion and/or exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single injection of mRNA-1345 and placebo, administered intramuscularly (IM), one in each arm on Day 1.
Biological: Placebo · Biological: mRNA-1345
Single injection of mRNA-1345 and Afluria® quadrivalent, administered IM, one in each arm on Day 1.
Biological: mRNA-1345 · Biological: Afluria® Quadrivalent
Single injection of Afluria® quadrivalent and placebo, administered IM, one in each arm on Day 1.
Biological: Placebo · Biological: Afluria® Quadrivalent
Single injection of mRNA-1345 and placebo, administered IM, one in each arm on Day 1. An additional injection of mRNA-1273.214, administered on Day 29.
Biological: Placebo · Biological: mRNA-1345 · Biological: mRNA-1273.214
Single injection of mRNA-1345 and mRNA-1273.214, administered IM, one in each arm on Day 1. An additional injection of placebo administered on Day 29.
Biological: Placebo · Biological: mRNA-1345 · Biological: mRNA-1273.214
Single injection of mRNA-1273.214 and placebo, administered IM, one in each arm on Day 1. An additional injection of placebo administered on Day 29.
Biological: Placebo · Biological: mRNA-1273.214
Single injection of mRNA-1345 administered IM on BD Day 1.
Biological: mRNA-1345
0.9% sodium chloride (normal saline) injection
Sterile liquid for injection
single-dose, pre-filled syringe for injection
Sterile liquid for injection
Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection
Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Within 7 days after Day 1 injection
Part A: Number of Participants With Unsolicited Adverse Events (AEs) After Day 1 Injection
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Day 1 through Day 28 (28 days after Day 1 injection)
Part A: Number of Participants With Medically Attended AEs (MAAEs), SAEs, Adverse Events of Special Interest (AESIs), and AEs Leading to Withdrawal
A MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner. An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Day 1 through Day 181 (end of Study Part A)
Part A: Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) Neutralizing Antibodies (NAbs) at Day 29
Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 13 international units (IU)/milliliter (mL) and ULOQ was 259061 IU/mL for RSV-A. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Day 29
Part A: Percentage of Participants With Seroresponse in RSV-A NAbs at Day 29
Seroresponse was defined as ≥4 × lower limit of quantification (LLOQ) if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Day 29
Part A: GMT of Serum Anti-hemagglutination (HA) Ab Level, as Measured by Hemagglutination Inhibition (HAI) Assay for Influenza at Day 29
Influenza A strains included H1N1 and H3N2 and influenza B strains included Washington and Phuket strains. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B. As prespecified, only arms where participants received Afluria® Quadrivalent are presented for this outcome measure.
Time frame: Day 29
Part B: Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 1 Injection
Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Within 7 days after Day 1 injection
Part B: Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 29 Injection
Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Within 7 days after Day 29 injection
Part B: Number of Participants With Unsolicited AEs After Day 1 Injection
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or PT/PTT) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Day 1 through Day 28 (28 days after Day 1 injection)
Part B: Number of Participants With Unsolicited AEs After Day 29 Injection
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Day 29 through Day 57 (28 days after Day 29 injection)
Part B: Number of Participants With MAAEs, SAEs, AESIs, and AEs Leading to Withdrawal
A MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner. An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Day 1 through Day 211
Part B: GMT of Serum RSV-A at Day 29
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Day 29
Part B: Percentage of Participants With Seroresponse for RSV-A Neutralizing Abs From Baseline to Day 29
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Baseline to Day 29
Part B: Geometric Mean Concentration (GMC) of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 29
The model-based GM titer was estimated on ANCOVA model. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 arbitrary units (AU)/milliliters (mL) and ULOQ was 111433 AU/mL for Wuhan-Hu-1. LLOQ was 8 and ULOQ was B.1.1.529 for B1.1.529. As prespecified, only arms where participants received mRNA-1273.214 are presented for this outcome measure.
Time frame: Day 29
Part B: Percentage of Participants With Seroresponse for SARS-Cov-2 NAbs From Baseline to Day 29
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. mRNA-As prespecified, only arms where participants received mRNA-1273.214 are presented for this outcome measure.
Time frame: Baseline to Day 29
Part C: Number of Participants With Solicited Local and Systemic Within 7 Days After Revaccination Day 1
Solicited ARs were collected in an electronic eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Within 7 days after Day 1 revaccination
Part C: Number of Participants With Unsolicited AEs Within 28 Days After Revaccination Day 1
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or PT/PTT) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Revaccination Day 1 through Day 28 (28 days after revaccination Day 1)
Part C: Number of Participants With MAAEs
A MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner.
Time frame: Revaccination Day 1 through Day 181
Part C: Number of Participants With SAEs, AESIs, and AEs Leading to Withdrawal
An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Revaccination Day 1 through Day 361
Part C: GMT of Serum RSV-A and RSV-B NAbs mRNA-1345 Revaccination Day 29 Compared to Primary Vaccination Day 29
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 IU/mL for RSV-B. mRNA-1345 Revaccination Day 29 and mRNA-1345 primary vaccination Day 29 (received in Part B) are presented.
Time frame: Primary Vaccination Day 29 to Revaccination Day 29
Part A: GMT of Serum RSV-B NAbs at Day 29
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Day 29
Part A: Percentage of Participants With Seroresponse in RSV-B NAbs at Day 29
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Day 29
Part A: Percentage of Participants With Seroconversion in Influenza A and B Strains at Day 181
Influenza A strains included H1N1 and H3N2 and influenza B strains included Washington and Phuket strains. Seroconversion was defined as a titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline in the titers if Baseline was ≥1:10. As prespecified, only arms where participants received Afluria® Quadrivalent are presented for this outcome measure.
Time frame: Day 181
Part A: GMT of Serum RSV-A and RSV-B NAbs at Day 181
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Day 181
Part A: Geometric Mean Fold Rise (GMFR) of Serum RSV-A and RSV-B NAbs at Day 181
95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Day 181
Part A: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAb Titers at Day 181
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ.As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Day 181
Part A: Percentage of Participants With ≥2-fold Increases From Baseline in RSV-A and RSV-B NAb Titers at Day 181
≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Baseline to Day 181
Part A: GMT of Serum Anti-HA Ab Level, as Measured by HAI Assay for Influenza at Day 181
Influenza A strains included H1N1 and H3N2 and influenza B strains included Washington and Phuket strains. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B. As prespecified, only arms where participants received Afluria® Quadrivalent are presented for this outcome measure.
Time frame: Day 181
Part A: GMFR of Serum Anti-HA Ab Level, as Measured by HAI Assay for Influenza at Day 181
Influenza A strains included H1N1 and H3N2 and influenza B strains included Washington and Phuket strains. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B. 95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. As prespecified, only arms where participants received Afluria® Quadrivalent are presented for this outcome measure.
Time frame: Day 181
Part B: GMT of Serum RSV-B NAbs at Day 29
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Day 29
Part B: Percentage of Participants With Seroresponse in RSV-B NAbs From Baseline to Day 29
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Baseline to Day 29
Part B: GMT of Serum RSV-A and RSV-B NAbs at Day 181
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Day 181
Part B: GMFR of Serum RSV-A and RSV-B NAbs at Day 181
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Day 181
Part B: GMC of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 181
95% CI for GM value was calculated based on the t-distribution of the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL for Wuhan-Hu-1. LLOQ was 8 AU/mL and ULOQ was 24503 for B1.1.529.
Time frame: Day 181
Part B: GMFR of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 181
95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
Time frame: Day 181
Part B: Percentage of Participants With Seroresponse for SARS-Cov-2 NAbs From Baseline to Day 181
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 111433 for Wuhan-Hu-1. LLOQ was 8 and ULOQ was B.1.1.529 for B1.1.529.
Time frame: Baseline to Day 181
Part B: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAb Titers at Day 181
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Day 181
Part B: Percentage of Participants With ≥2-fold Increases From Baseline in RSV-A and RSV-B NAb Titers at Day 181
≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Baseline to Day 181
Part B: GMT of Serum RSV-A and RSV-B NAbs at Day 211
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Day 211
Part B: GMFR of Serum RSV-A and RSV-B NAbs at Day 211
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Day 211
Part B: GMC of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 211
95% CI for GM value was calculated based on the t-distribution of the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL for Wuhan-Hu-1. LLOQ was 8 AU/mL and ULOQ was 24503 for B1.1.529.
Time frame: Day 211
Part B: GMFR of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 211
95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
Time frame: Day 211
Part B: Percentage of Participants With Seroresponse for SARS-Cov-2 NAbs at Day 211
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 111433 for Wuhan-Hu-1. LLOQ was 8 and ULOQ was B.1.1.529 for B1.1.529.
Time frame: Day 211
Part B: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAb Titers at Day 211
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Day 211
Part B: Percentage of Participants With ≥2-fold Increases From Baseline in RSV-A and RSV-B NAb Titers at Day 211
≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
Time frame: Day 211
Part C: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAbs From Baseline (Before Primary Vaccination) to Revaccination Day 29
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. Primary vaccination Day 29 (received in Part B) and Revaccination Day 29 are presented.
Time frame: Baseline (Before Primary Vaccination in Part B) to Revaccination Day 29
Part C: GMT of Serum RSV-A and RSV-B NAbs at Revaccination Day 361
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 IU/mL for RSV-B.
Time frame: Revaccination Day 361
Part C: GMFR of Serum RSV-A and RSV-B NAbs at Revaccination Day 361
95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
Time frame: Revaccination Day 361
Part C: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAbs at Revaccination Day 361
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ.
Time frame: Baseline to Revaccination Day 361
Part C: Percentage of Participants With ≥2-fold Increases From Baseline (Before Primary Vaccination) in RSV-A and RSV-B NAb Titers at Revaccination Day 361
≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 IU/mL for RSV-B.
Time frame: Baseline to Revaccination Day 361
Number of Deaths During the Study
A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable and/or the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.
Time frame: Up to Day 181 for Part A, up to Day 211 for Part B, and up to Day 361 for Part C
| Milestone | Part A: mRNA-1345 + Placebo | Part A: mRNA-1345 + Afluria® Quadrivalent | Part A: Afluria® Quadrivalent + Placebo | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo | Part C: mRNA-1345 Revaccination |
|---|---|---|---|---|---|---|---|
| Started | 249 | 690 | 692 | 560 | 564 | 562 | 0 |
| Received at least 1 dose of any study injection | 249 | 685 | 689 | 556 | 562 | 558 | 0 |
| Part b day 1 injection | 0 | 0 | 0 | 556 | 562 | 558 | 0 |
| Part b day 29 injection | 0 | 0 | 0 | 530 | 535 | 536 | 0 |
| Safety set | 249 | 685 | 689 | 554 | 562 | 560 | 0 |
| Solicited safety set (day 1 injection) | 249 | 678 | 683 | 553 | 562 | 557 | 0 |
| Part b solicited safety set day 29 injection | 0 | 0 | 0 | 522 | 532 | 528 | 0 |
| Per-protocol (pp) set | 232 | 639 | 626 | 513 | 514 | 519 | 0 |
| Completed | 233 | 652 | 643 | 500 | 516 | 510 | 0 |
| Not completed | 16 | 38 | 49 | 60 | 48 | 52 | 0 |
| Withdrew: Lost to follow-up | 12 | 21 | 38 | 30 | 25 | 28 | 0 |
| Withdrew: Withdrawal by subject | 4 | 11 | 8 | 23 | 20 | 19 | 0 |
| Withdrew: Protocol violation | 0 | 2 | 0 | 4 | 0 | 3 | 0 |
| Withdrew: Death | 0 | 3 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Other than specified | 0 | 1 | 2 | 1 | 2 | 2 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Part A: mRNA-1345 + Placebo | Part A: mRNA-1345 + Afluria® Quadrivalent | Part A: Afluria® Quadrivalent + Placebo | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo | Part C: mRNA-1345 Revaccination |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 543 |
| Part c safety set | 0 | 0 | 0 | 0 | 0 | 0 | 543 |
| Part c solicited safety set | 0 | 0 | 0 | 0 | 0 | 0 | 543 |
| Part c pp set | 0 | 0 | 0 | 0 | 0 | 0 | 525 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 525 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 18 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 10 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| IU/mL | Part A: mRNA-1345 + Placebo | Part A: mRNA-1345 + Afluria® Quadrivalent |
|---|---|---|
| Part A: GMT of Serum RSV-B NAbs at Day 29 | 10436.03 (8973.29 to 12137.20) | 8909.80 (8016.02 to 9903.24) |
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| percentage of participants | Part A: mRNA-1345 + Placebo | Part A: mRNA-1345 + Afluria® Quadrivalent |
|---|---|---|
| Part A: Percentage of Participants With Seroresponse in RSV-B NAbs at Day 29 | 63.8 (57.2 to 70.0) | 49.5 (45.5 to 53.4) |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Washington and Phuket strains. Seroconversion was defined as a titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline in the titers if Baseline was ≥1:10. As prespecified, only arms where participants received Afluria® Quadrivalent are presented for this outcome measure.
| percentage of participants | Part A: mRNA-1345 + Afluria® Quadrivalent | Part A: Afluria® Quadrivalent + Placebo |
|---|---|---|
| Influenza A H1N1 Antibody | 41.1 (37.1 to 45.1) | 38.8 (34.9 to 42.9) |
| Influenza A H3N2 Antibody | 29.4 (25.8 to 33.2) | 28.7 (25.1 to 32.6) |
| Influenza B Washington Antibody | 19.5 (16.5 to 22.9) | 19.7 (16.5 to 23.1) |
| Influenza B Phuket Antibody | 17.2 (14.3 to 20.5) | 18.8 (15.8 to 22.2) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| IU/mL | Part A: mRNA-1345 + Placebo | Part A: mRNA-1345 + Afluria® Quadrivalent |
|---|---|---|
| RSV-A | 7551.13 (6504.13 to 8766.68) | 6429.48 (5850.16 to 7066.17) |
| RSV-B | 2402.86 (2120.18 to 2723.23) | 2301.47 (2114.95 to 2504.44) |
95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| ratio | Part A: mRNA-1345 + Placebo | Part A: mRNA-1345 + Afluria® Quadrivalent |
|---|---|---|
| RSV-A | 3.46 (2.97 to 4.04) | 2.19 (1.99 to 2.40) |
| RSV-B | 1.32 (1.17 to 1.49) | 0.94 (0.87 to 1.02) |
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ.As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| percentage of participants | Part A: mRNA-1345 + Placebo | Part A: mRNA-1345 + Afluria® Quadrivalent |
|---|---|---|
| RSV-A | 46.8 (40.0 to 53.6) | 29.9 (26.3 to 33.7) |
| RSV-B | 13.3 (9.1 to 18.5) | 6.7 (4.8 to 9.0) |
≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| percentage of participants | Part A: mRNA-1345 + Placebo | Part A: mRNA-1345 + Afluria® Quadrivalent |
|---|---|---|
| RSV-A | 67.0 (60.3 to 73.2) | 54.1 (50.0 to 58.1) |
| RSV-B | 32.1 (26.0 to 38.7) | 21.0 (17.9 to 24.5) |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Washington and Phuket strains. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B. As prespecified, only arms where participants received Afluria® Quadrivalent are presented for this outcome measure.
| titer | Part A: mRNA-1345 + Afluria® Quadrivalent | Part A: Afluria® Quadrivalent + Placebo |
|---|---|---|
| Influenza A H1N1 Antibody | 155.59 (138.10 to 175.31) | 156.47 (139.65 to 175.33) |
| Influenza A H3N2 Antibody | 113.58 (101.54 to 127.06) | 109.36 (98.28 to 121.68) |
| Influenza B Washington Antibody | 32.11 (29.10 to 35.43) | 35.03 (31.76 to 38.64) |
| Influenza B Phuket Antibody | 25.64 (23.34 to 28.17) | 26.43 (24.17 to 28.91) |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Washington and Phuket strains. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B. 95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. As prespecified, only arms where participants received Afluria® Quadrivalent are presented for this outcome measure.
| ratio | Part A: mRNA-1345 + Afluria® Quadrivalent | Part A: Afluria® Quadrivalent + Placebo |
|---|---|---|
| Influenza A H1N1 Antibody | 3.21 (2.80 to 3.68) | 3.08 (2.70 to 3.51) |
| Influenza A H3N2 Antibody | 2.28 (2.04 to 2.55) | 2.23 (2.00 to 2.49) |
| Influenza B Washington Antibody | 1.80 (1.66 to 1.96) | 1.95 (1.79 to 2.13) |
| Influenza B Phuket Antibody | 1.76 (1.63 to 1.90) | 1.79 (1.66 to 1.93) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| IU/mL | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo |
|---|---|---|
| Part B: GMT of Serum RSV-B NAbs at Day 29 | 6584.54 (5961.73 to 7272.40) | 5843.94 (5292.14 to 6453.28) |
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| percentage of participants | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo |
|---|---|---|
| Part B: Percentage of Participants With Seroresponse in RSV-B NAbs From Baseline to Day 29 | 51.9 (47.4 to 56.3) | 46.0 (41.6 to 50.4) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| IU/mL | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo |
|---|---|---|
| RSV-A | 6456.32 (5830.84 to 7148.91) | 5221.87 (4723.14 to 5773.26) |
| RSV-B | 2447.67 (2236.91 to 2678.28) | 2274.83 (2070.95 to 2498.79) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| ratio | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo |
|---|---|---|
| RSV-A | 2.91 (2.65 to 3.20) | 2.58 (2.36 to 2.82) |
| RSV-B | 1.61 (1.48 to 1.75) | 1.49 (1.38 to 1.61) |
95% CI for GM value was calculated based on the t-distribution of the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL for Wuhan-Hu-1. LLOQ was 8 AU/mL and ULOQ was 24503 for B1.1.529.
| AU/mL | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo |
|---|---|---|---|
| Wuhan-Hu-1 | 4075.34 (3722.53 to 4461.58) | 3615.45 (3272.04 to 3994.91) | 3665.39 (3335.37 to 4028.07) |
| B.1.1.529 | 1002.35 (894.17 to 1123.61) | 889.75 (791.84 to 999.76) | 919.49 (820.46 to 1030.46) |
95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
| ratio | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo |
|---|---|---|---|
| Wuhan-Hu-1 | 2.12 (1.90 to 2.38) | 1.94 (1.72 to 2.19) | 1.84 (1.65 to 2.06) |
| B.1.1.529 | 3.57 (3.12 to 4.09) | 3.27 (2.83 to 3.78) | 3.13 (2.75 to 3.55) |
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 111433 for Wuhan-Hu-1. LLOQ was 8 and ULOQ was B.1.1.529 for B1.1.529.
| percentage of participants | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo |
|---|---|---|---|
| Wuhan-Hu-1 | 24.1 (20.3 to 28.2) | 23.6 (19.9 to 27.7) | 19.8 (16.4 to 23.7) |
| B.1.1.529 | 44.7 (40.2 to 49.3) | 41.0 (36.6 to 45.6) | 40.5 (36.1 to 45.0) |
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| percentage of participants | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo |
|---|---|---|
| RSV-A | 34.9 (30.6 to 39.3) | 30.2 (26.1 to 34.5) |
| RSV-B | 14.9 (11.9 to 18.5) | 12.7 (9.9 to 16.0) |
≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| percentage of participants | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo |
|---|---|---|
| RSV-A | 62.8 (58.3 to 67.2) | 58.3 (53.8 to 62.7) |
| RSV-B | 36.4 (32.1 to 40.9) | 35.7 (31.5 to 40.2) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| IU/mL | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo |
|---|---|---|
| RSV-A | 5921.09 (5357.33 to 6544.17) | 4696.74 (4245.92 to 5195.44) |
| RSV-B | 2261.26 (2069.70 to 2470.56) | 2132.70 (1943.36 to 2340.49) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| ratio | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo |
|---|---|---|
| RSV-A | 2.71 (2.48 to 2.98) | 2.35 (2.15 to 2.56) |
| RSV-B | 1.50 (1.39 to 1.63) | 1.40 (1.30 to 1.51) |
95% CI for GM value was calculated based on the t-distribution of the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL for Wuhan-Hu-1. LLOQ was 8 AU/mL and ULOQ was 24503 for B1.1.529.
| AU/mL | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo |
|---|---|---|---|
| Wuhan-Hu-1 | 3551.74 (3245.10 to 3887.35) | 3034.11 (2743.48 to 3355.54) | 3123.69 (2841.55 to 3433.84) |
| B.1.1.529 | 923.10 (826.89 to 1030.51) | 797.17 (708.18 to 897.33) | 795.90 (709.19 to 893.21) |
95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
| ratio | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo |
|---|---|---|---|
| Wuhan-Hu-1 | 1.87 (1.66 to 2.09) | 1.64 (1.45 to 1.85) | 1.59 (1.42 to 1.77) |
| B.1.1.529 | 3.31 (2.90 to 3.79) | 2.95 (2.56 to 3.40) | 2.72 (2.39 to 3.10) |
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 111433 for Wuhan-Hu-1. LLOQ was 8 and ULOQ was B.1.1.529 for B1.1.529.
| percentage of participants | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo |
|---|---|---|---|
| Wuhan-Hu-1 | 21.1 (17.5 to 25.1) | 20.3 (16.7 to 24.1) | 17.8 (14.5 to 21.5) |
| B.1.1.529 | 41.4 (36.9 to 46.0) | 38.8 (34.4 to 43.3) | 37.0 (32.7 to 41.5) |
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| percentage of participants | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo |
|---|---|---|
| RSV-A | 32.5 (28.3 to 36.9) | 26.5 (22.7 to 30.7) |
| RSV-B | 12.3 (9.5 to 15.6) | 10.1 (7.5 to 13.1) |
≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| percentage of participants | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo |
|---|---|---|
| RSV-A | 57.8 (53.2 to 62.3) | 53.7 (49.2 to 58.2) |
| RSV-B | 33.7 (29.4 to 38.1) | 30.6 (26.5 to 34.9) |
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. Primary vaccination Day 29 (received in Part B) and Revaccination Day 29 are presented.
| percentage of participants | Part C: mRNA-1345 Primary Vaccination | Part C: mRNA-1345 Revaccincation |
|---|---|---|
| RSV-A | 75.3 (71.3 to 78.9) | 77.5 (73.7 to 81.0) |
| RSV-B | 48.2 (43.8 to 52.6) | 47.5 (43.2 to 51.9) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 IU/mL for RSV-B.
| IU/mL | Part C: mRNA-1345 Revaccincation |
|---|---|
| RSV-A | 4708.27 (4279.78 to 5179.67) |
| RSV-B | 2251.24 (2054.09 to 2467.32) |
95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
| ratio | Part C: mRNA-1345 Revaccincation |
|---|---|
| RSV-A | 2.26 (2.06 to 2.48) |
| RSV-B | 1.42 (1.31 to 1.53) |
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ.
| percentage of participants | Part C: mRNA-1345 Revaccincation |
|---|---|
| RSV-A | 25.8 (22.0 to 29.9) |
| RSV-B | 11.5 (8.8 to 14.6) |
≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 IU/mL for RSV-B.
| percentage of participants | Part C: mRNA-1345 Revaccincation |
|---|---|
| RSV-A | 53.0 (48.5 to 57.5) |
| RSV-B | 32.7 (28.5 to 37.0) |
Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part A: mRNA-1345 + Placebo | Part A: mRNA-1345 + Afluria® Quadrivalent | Part A: Afluria® Quadrivalent + Placebo |
|---|---|---|---|
| Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection | 147 | 395 | 291 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part A: mRNA-1345 + Placebo | Part A: mRNA-1345 + Afluria® Quadrivalent | Part A: Afluria® Quadrivalent + Placebo |
|---|---|---|---|
| Part A: Number of Participants With Unsolicited Adverse Events (AEs) After Day 1 Injection | 21 | 57 | 46 |
A MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner. An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part A: mRNA-1345 + Placebo | Part A: mRNA-1345 + Afluria® Quadrivalent | Part A: Afluria® Quadrivalent + Placebo |
|---|---|---|---|
| MAAE | 41 | 136 | 114 |
| SAE | 4 | 28 | 24 |
| AESI | 0 | 1 | 1 |
| AEs Leading to Withdrawal | 0 | 3 | 1 |
Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 13 international units (IU)/milliliter (mL) and ULOQ was 259061 IU/mL for RSV-A. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| IU/mL | Part A: mRNA-1345 + Placebo | Part A: mRNA-1345 + Afluria® Quadrivalent |
|---|---|---|
| Part A: Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) Neutralizing Antibodies (NAbs) at Day 29 | 17271.72 (14448.78 to 20646.20) | 13929.98 (12291.04 to 15787.47) |
Seroresponse was defined as ≥4 × lower limit of quantification (LLOQ) if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| percentage of participants | Part A: mRNA-1345 + Placebo | Part A: mRNA-1345 + Afluria® Quadrivalent |
|---|---|---|
| Part A: Percentage of Participants With Seroresponse in RSV-A NAbs at Day 29 | 72.4 (66.2 to 78.1) | 61.2 (57.3 to 65.0) |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Washington and Phuket strains. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B. As prespecified, only arms where participants received Afluria® Quadrivalent are presented for this outcome measure.
| titer | Part A: mRNA-1345 + Afluria® Quadrivalent | Part A: Afluria® Quadrivalent + Placebo |
|---|---|---|
| Influenza A H1N1 Antibody | 271.27 (239.71 to 306.99) | 303.92 (268.24 to 344.35) |
| Influenza A H3N2 Antibody | 144.14 (130.37 to 159.36) | 148.69 (134.35 to 164.55) |
| Influenza B Washington Antibody | 57.59 (52.01 to 63.77) | 62.13 (56.05 to 68.86) |
| Influenza B Phuket Antibody | 38.52 (34.91 to 42.50) | 42.40 (38.39 to 46.82) |
Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo |
|---|---|---|---|
| Part B: Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 1 Injection | 358 | 394 | 361 |
Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo |
|---|---|---|---|
| Part B: Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 29 Injection | 265 | 147 | 148 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or PT/PTT) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo |
|---|---|---|---|
| Part B: Number of Participants With Unsolicited AEs After Day 1 Injection | 41 | 54 | 44 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo |
|---|---|---|---|
| Part B: Number of Participants With Unsolicited AEs After Day 29 Injection | 31 | 25 | 26 |
A MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner. An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo |
|---|---|---|---|
| MAAEs | 109 | 107 | 97 |
| SAEs | 18 | 13 | 10 |
| AESIs | 5 | 2 | 7 |
| AEs Leading to Withdrawal | 1 | 0 | 0 |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| IU/mL | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo |
|---|---|---|
| Part B: GMT of Serum RSV-A at Day 29 | 19071.03 (17130.14 to 21231.84) | 15171.23 (13626.94 to 16890.53) |
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.
| percentage of participants | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo |
|---|---|---|
| Part B: Percentage of Participants With Seroresponse for RSV-A Neutralizing Abs From Baseline to Day 29 | 75.4 (71.4 to 79.1) | 70.9 (66.8 to 74.9) |
The model-based GM titer was estimated on ANCOVA model. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 arbitrary units (AU)/milliliters (mL) and ULOQ was 111433 AU/mL for Wuhan-Hu-1. LLOQ was 8 and ULOQ was B.1.1.529 for B1.1.529. As prespecified, only arms where participants received mRNA-1273.214 are presented for this outcome measure.
| AU/mL | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo |
|---|---|---|
| Wuhan-Hu-1 | 9881.69 (9097.35 to 10733.66) | 10300.49 (9490.13 to 11180.04) |
| B.1.1.529 | 2353.15 (2115.26 to 2617.80) | 2342.87 (2107.26 to 2604.82) |
Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. mRNA-As prespecified, only arms where participants received mRNA-1273.214 are presented for this outcome measure.
| percentage of participants | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo |
|---|---|---|
| Wuhan-Hu-1 | 52.7 (48.2 to 57.1) | 52.5 (48.1 to 56.9) |
| B.1.1.529 | 68.4 (64.2 to 72.4) | 69.4 (65.2 to 73.3) |
Solicited ARs were collected in an electronic eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part C: mRNA-1345 Revaccincation |
|---|---|
| Part C: Number of Participants With Solicited Local and Systemic Within 7 Days After Revaccination Day 1 | 338 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or PT/PTT) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part C: mRNA-1345 Revaccincation |
|---|---|
| Part C: Number of Participants With Unsolicited AEs Within 28 Days After Revaccination Day 1 | 31 |
A MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner.
| Participants | Part C: mRNA-1345 Revaccincation |
|---|---|
| Part C: Number of Participants With MAAEs | 105 |
An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part C: mRNA-1345 Revaccincation |
|---|---|
| SAEs | 28 |
| AESIs | 2 |
| AEs Leading to Withdrawal | 5 |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 IU/mL for RSV-B. mRNA-1345 Revaccination Day 29 and mRNA-1345 primary vaccination Day 29 (received in Part B) are presented.
| IU/mL | Part C: mRNA-1345 Primary Vaccination | Part C: mRNA-1345 Revaccincation |
|---|---|---|
| RSV-A | 18190.30 (16467.13 to 20093.79) | 19649.18 (18017.92 to 21428.12) |
| RSV-B | 6746.41 (6136.32 to 7417.16) | 6123.47 (5599.77 to 6696.14) |
A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable and/or the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.
| Participants | Part A: mRNA-1345 + Placebo | Part A: mRNA-1345 + Afluria® Quadrivalent | Part A: Afluria® Quadrivalent + Placebo | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo | Part C: mRNA-1345 Revaccination |
|---|---|---|---|---|---|---|---|
| Deaths | 0 | 3 | 1 | 1 | 0 | 0 | 3 |
| Deaths related to study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over All-cause mortality and serious adverse events were collected throughout the entire period of the study (up to Day 181 for Part A, up to Day 211 for Part B, and up to Day 361 for Part C). Other (not including serious) adverse events were collected for 28 days after the vaccination unless they met the criteria for AESIs, MAAEs or AEs led to discontinuation.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: mRNA-1345 + Placebo | 0/249 (0%) | 4/249 (1.6%) | 0/249 (0%) |
| Part A: mRNA-1345 + Afluria Quadrivalent | 3/690 (0.4%) | 28/685 (4.1%) | 0/685 (0%) |
| Part A: Afluria Quadrivalent + Placebo | 1/692 (0.1%) | 24/689 (3.5%) | 0/689 (0%) |
| Part B: mRNA-1345 + Placebo + mRNA-1273.214 | 1/560 (0.2%) | 18/554 (3.2%) | 0/554 (0%) |
| Part B: mRNA-1345 + mRNA-1273.214 + Placebo | 0/564 (0%) | 13/562 (2.3%) | 0/562 (0%) |
| Part B: mRNA-1273.214 + Placebo + Placebo | 0/562 (0%) | 10/560 (1.8%) | 0/560 (0%) |
| Part C: Revaccination | 3/543 (0.6%) | 28/543 (5.2%) | 0/543 (0%) |
| Event | Part A: mRNA-1345 + Placebo | Part A: mRNA-1345 + Afluria Quadrivalent | Part A: Afluria Quadrivalent + Placebo | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo | Part C: Revaccination |
|---|---|---|---|---|---|---|---|
| CellulitisInfections and infestations | 0/249 | 2/685 | 0/689 | 1/554 | 2/562 | 0/560 | 3/543 |
| SepsisInfections and infestations | 0/249 | 3/685 | 1/689 | 0/554 | 0/562 | 0/560 | 1/543 |
| Pituitary tumour benignNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/249 | 0/685 | 0/689 | 0/554 | 0/562 | 0/560 | 0/543 |
| Acute myocardial infarctionCardiac disorders | 1/249 | 0/685 | 0/689 | 0/554 | 1/562 | 0/560 | 1/543 |
| HypertensionVascular disorders | 1/249 | 1/685 | 0/689 | 0/554 | 0/562 | 0/560 | 0/543 |
| Portal hypertensionHepatobiliary disorders | 1/249 | 0/685 | 0/689 | 0/554 | 0/562 | 0/560 | 0/543 |
| Skin ulcerSkin and subcutaneous tissue disorders | 1/249 | 0/685 | 0/689 | 0/554 | 0/562 | 0/560 | 0/543 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/249 | 0/685 | 0/689 | 0/554 | 0/562 | 1/560 | 0/543 |
| PneumoniaInfections and infestations | 0/249 | 1/685 | 0/689 | 2/554 | 0/562 | 0/560 | 2/543 |
| Septic shockInfections and infestations | 0/249 | 0/685 | 1/689 | 0/554 | 0/562 | 0/560 | 2/543 |
Randomized Set included all participants who were randomized in the study, regardless of the participant's treatment status in the study.
| Age, Customized(years) | Part A: mRNA-1345 + Placebo | Part A: mRNA-1345 + Afluria® Quadrivalent | Part A: Afluria® Quadrivalent + Placebo | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo | Total |
|---|---|---|---|---|---|---|---|
| ≥50 years of age | 249 | 690 | 692 | 560 | 564 | 562 | 3317 |
| Sex: Female, Male(Participants) | Part A: mRNA-1345 + Placebo | Part A: mRNA-1345 + Afluria® Quadrivalent | Part A: Afluria® Quadrivalent + Placebo | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 141 | 367 | 375 | 315 | 317 | 296 | 1811 |
| Male | 108 | 323 | 317 | 245 | 247 | 266 | 1506 |
| Ethnicity (NIH/OMB)(Participants) | Part A: mRNA-1345 + Placebo | Part A: mRNA-1345 + Afluria® Quadrivalent | Part A: Afluria® Quadrivalent + Placebo | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 91 | 240 | 249 | 213 | 214 | 223 | 1230 |
| Not Hispanic or Latino | 158 | 445 | 442 | 342 | 349 | 333 | 2069 |
| Unknown or Not Reported | 0 | 5 | 1 | 5 | 1 | 6 | 18 |
| Race/Ethnicity, Customized(Participants) | Part A: mRNA-1345 + Placebo | Part A: mRNA-1345 + Afluria® Quadrivalent | Part A: Afluria® Quadrivalent + Placebo | Part B: mRNA-1345 + Placebo + mRNA-1273.214 | Part B: mRNA-1345 + mRNA-1273.214 + Placebo | Part B: mRNA-1273.214 + Placebo + Placebo | Total |
|---|---|---|---|---|---|---|---|
| Race — White | 189 | 524 | 514 | 430 | 428 | 438 | 2523 |
| Race — Black or African American | 59 | 157 | 166 | 112 | 113 | 111 | 718 |
| Race — Asian | 0 | 4 | 3 | 6 | 8 | 1 | 22 |
| Race — American Indian or Alaska Native | 1 | 1 | 4 | 6 | 4 | 2 | 18 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 1 | 3 | 1 | 3 | 0 | 8 |
| Race — Other | 0 | 1 | 1 | 1 | 0 | 3 | 6 |
| Race — Multiple | 0 | 2 | 0 | 1 | 0 | 3 | 6 |
| Race — Not Reported | 0 | 0 | 1 | 3 | 8 | 4 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2022 to primary completion in Nov 2024, 31 months.
Results were first posted in Dec 2025, 1 year 1 month after primary completion.
Of 40 industry-sponsored phase 3 interventional studies under Virus Diseases, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 24. This study's 31 months is above that.
Counting every sponsor, half of 57 studies reached it within 14 months; a quarter within 8 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: mRNA-1345 respiratory syncytial virus vaccine · mRNA-1273.214 COVID-19 vaccine